BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

AI Briefing

• – BBP-418 treatment shows promising results for LGMD2I/R9, with interim Phase 3 trial data demonstrating significant improvements in ambulation and pulmonary function.
• – BridgeBio submits NDA to FDA for BBP-418, a potential treatment for individuals living with LGMD2I/R9.
• – Interim trial results highlight a favorable safety profile for BBP-418, providing a promising therapeutic option for this rare disease.